Vanguard Fiduciary Trust
INMB icon

Vanguard Fiduciary Trust’s INmune Bio INMB Stock Holding History

Vanguard Fiduciary Trust’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$171K Sell
104,775
-18,409
-15% -$25.5K ﹤0.01% 3618
2026
Q1 		$139K Buy
+123,184
New +$176K ﹤0.01% 3624

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Fiduciary Trust's INMB Position: Q2 2026 in Review

Vanguard Fiduciary Trust reduced its INmune Bio (INMB) stake by 15% in Q2 2026, selling an estimated $25.5K and leaving 104,775 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #3618.

Vanguard Fiduciary Trust first reported a position in INMB in Q1 2026 and has held it in 2 quarters since. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Vanguard Fiduciary Trust held 104,775 shares of INmune Bio worth $171K as of Q2 2026.
  • Vanguard Fiduciary Trust sold 18,409 INmune Bio shares in Q2 2026, an estimated $25.5K.
  • INmune Bio made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3618 holding.
  • Vanguard Fiduciary Trust first reported a position in INmune Bio in Q1 2026 and has held it in 2 quarters since.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.